| Document |
Document Title |
|
WO/2004/076424A1 |
Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
|
|
WO/2004/074438A2 |
The invention relates to certain substituted bicyclicaryl-benzenesulfonamide and their use for inhibiting the chemokine receptor nominated CCR8. The generic structure for these compounds, as defined herein is that of a benzenesulfonamide...
|
|
WO/2004/073619A2 |
This invention relates to certain substituted benzenesulfonamide and their use for inhibiting the chemokine receptor nominated CCR8. The generic structure for these compounds, as defined herein is that of a benzenesulfonamide of formula ...
|
|
WO/2004/069826A1 |
The invention relates to malonamide derivatives of formula (IA) or (IB) and to pharmaceutically suitable acid addition salts thereof. The compounds are &gammad -secretase inhibitors and the related compounds may be useful in the treatmen...
|
|
WO/2004/069197A2 |
The invention relates to new 2,3-benzodiazepine derivatives of formula (I), isomers and acid addition salts thereof and to pharmaceutical compositions containing the same, as well as to pharmaceutical compositions and methods of using th...
|
|
WO/2004/065382A1 |
Pharmaceutically active diazepanes, e.g. useful for treating disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.
|
|
WO/2004/065390A1 |
The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.
|
|
WO/2004/065591A1 |
This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by ...
|
|
WO/2004/063163A1 |
Compounds of Formula (I) wherein R1, R2 R3, R4, R5, R6, and X are as defiend herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods o...
|
|
WO/2004/060376A1 |
The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibitin...
|
|
WO/2004/060308A2 |
Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel method...
|
|
WO/2004/058164A2 |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...
|
|
WO/2004/056182A1 |
Use of compounds of formula (I): wherein X is S, O, S=O, SO2, NRa, or CRbRc;R1,R2 are halogen, OH, SH, NH2, CN, NO2, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy,...
|
|
WO/2004/056744A1 |
formulae (I)the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R1 and R2 each independently represents hydrogen C1-4alkyl, NR9R...
|
|
WO/2004/056745A2 |
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; R1 and R2 each independently represents hydrogen C1-4alkyl, NR9R10, C1-4alky...
|
|
WO/2004/056319A2 |
Disclosed are certain substituted N-phenylsulfonamide derivatives and related compounds. These compounds are useful as bradykinin antagonists to relieve adverse symptoms in mammals mediated, at least in part, by bradykinin including pain...
|
|
WO/2004/041258A2 |
The invention concerns the use of PDE2 inhibitors for treating disorders of the central and peripheral nervous system, a method for therapeutic treatment by administering to an animal said inhibitors. More specifically, the invention con...
|
|
WO/2004/041286A1 |
The invention provides compositions and methods for altering insulin secretion using a compound that inhibits calcium efflux via the mitochondrial calcium/ sodium antiporter (MCA). Methods of treatment are thereby provided, and are parti...
|
|
WO/2004/037800A1 |
The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
|
WO/2004/037169A2 |
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is...
|
|
WO/2004/035556A1 |
The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders ...
|
|
WO/2004/033436A1 |
Disclosed are compounds, of formula (I) which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit ...
|
|
WO/2004/032930A1 |
A therapeutic drug for cancers which contains as an active ingredient a cyclic diamine compound represented by the following general formula (1): (1) [wherein R1 and R2 each represents hydrogen or methoxy, provided that when R2 represent...
|
|
WO/2004/026843A1 |
Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: - R1 represents C1-6 alkyl, aryl or heteroaryl; - R2 represents hydrogen or C1-6 alkyl; - e...
|
|
WO/2004/022563A1 |
The invention concerns novel heterocyclic compounds of formula (1), and their salts with a base or an acid. The invention also concerns the method as well as the intermediates for preparing said compounds, and their use as medicines, in ...
|
|
WO/2004/019946A1 |
An inhibitor for the excessive accumulation of sodium ion in cells and a remedy and/or a preventive for heart disorders accompanying a heart surgery comprising, as the active ingredient, an aminobenzenesulfonic acid derivative represente...
|
|
WO/2004/018058A2 |
Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.
|
|
WO/2004/012648A2 |
The invention relates to substituted diaryl heterocycles and the physiologically compatible salts and physiologically functional derivates thereof. The invention also relates to compounds of formula (I), wherein the radicals have the abo...
|
|
WO/2004/011438A1 |
The invention relates to substituted diaryl heterocycles and the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to compounds of formula (I) wherein the radicals have the ci...
|
|
WO/2004/002493A1 |
Abstract The present invention is directed to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin. The agent contains, as an active ingredient, N,N'-bis(5-(3,4,5-trimethoxyphenyl)-...
|
|
WO/2004/001058A2 |
Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: 1) a selectable marker un...
|
|
WO/2003/106444A1 |
N,N-Disubstituted diazocycloalkanes of the formula (I): (R1 = halogen, R2 = (C3-C8)-cycloalkyl, R3 = (C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2, n is 1 or 2) have affinity for serotoninergic receptors. These compounds and th...
|
|
WO/2003/106428A1 |
The invention relates to a) arylsulphonamide compounds as given by formula (I), where R1 = an aromatic nucleus, non-substituted or substituted by one or several atoms selected from the halogens, C1 C3 alkyl, C1 C3 alkoxy, nitro, cyano, t...
|
|
WO/2003/106628A2 |
Compounds having the formula (I), are useful as inhibitors of mitochondrial F¿1?F¿0? ATP hydrolase, wherein R1, R5 and R7 are optional substituents, R¿2?, R¿3? and R¿4? are hydrogen, alkyl, or substituted alkyl, or comprise a bond t...
|
|
WO/2003/099797A1 |
The present invention provides compounds of the Formula (I): wherein X is selected from HCI, HOC(O)CF3, cis-HO(CO)-CH=CH-(CO)OH, and Formula (II). In another aspect, the invention further provides a pharmaceutical composition including a...
|
|
WO/2003/096989A2 |
Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided....
|
|
WO/2003/090690A2 |
Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for th...
|
|
WO/2003/090691A2 |
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Composit...
|
|
WO/2003/091264A2 |
Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit reverse transcriptase activity and are useful therapeutically for th...
|
|
WO/2003/084610A1 |
The present invention provides for a pharmaceutical composition and methods for treating psychosis comprising the combination or a first component which is an atypical antipsychotic with a second component which is a mGlu2/3 receptor ago...
|
|
WO/2003/082832A2 |
Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects. Compounds of e.g. the foll...
|
|
WO/2003/082877A1 |
Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene option...
|
|
WO/2003/076422A1 |
This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing th...
|
|
WO/2003/074476A1 |
An arylamidine derivative represented by the general formula (1) (wherein X means optionally substituted lower alkylene or alkenylene; G1 means oxygen, sulfur, or imino; G2 means carbon or nitrogen; Ra means at least one member selected ...
|
|
WO/2003/072558A2 |
The invention provides compounds of the formula (I) and methods of using those compounds for treating a disease or condition in a mammal wherein a 5-HT receptor, such as a 5-HT¿6? receptor, is implicated and modulation of a 5-HT functio...
|
|
WO/2003/062819A2 |
A water-soluble reference standard is useful for immunoassays of a lipophilic drugs. The reference standard is a compound of the following formula: G-(L)nY ; where G is a lipophilic drug; L is a linker which is an alkyl group or heteroal...
|
|
WO/2003/062228A1 |
The present invention discloses novel compounds of Formula I which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprisi...
|
|
WO/2003/062226A1 |
Compounds of Formula I including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof, are disclosed which are useful as invertebrate pest control agents, (I) wherein A, B, J, K, L and R3 are as defined in...
|
|
WO/2003/053366A2 |
The subject invention provides compounds having the structure:, wherein R1 is substituted or unsubstituted phenyl or a 5−6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms&semi R2 is hydrogen, or a substi...
|
|
WO/2003/051275A2 |
A method of treating pain in a warm-blooded animal, comprising the step ofadministering to said animal a therapeutically effective amount of a compound of formula(I), pharmaceutically acceptable salts thereof, diasteriomers thereof, enan...
|
